-

Inovio Pharmaceuticals, Inc. (INO) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO) investors concerning the Company’s possible violations of federal securities laws.

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN INOVIO PHARMACEUTICALS, INC. (INO), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@howardsmithlaw.com, by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.

What Happened?

On August 8, 2024, after market hours, Inovio released its second quarter 2024 financial results, revealing that it expected to submit the Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (‘FDA”) for its recurrent respiratory papillomatosis “RPR”) treatment, INO-3107, in mid-2025, despite previous claims of a mid-2024 submission, due to a “manufacturing issue” with a component of the Company’s proprietary investigational medical device, CELLECTRA.

On this news, Inovio’s stock price fell $0.27, or 3.1%, to close at $8.44 per share on August 9, 2024, thereby injuring investors.

Then, on December 29, 2025, Inovio disclosed that the FDA had accepted the INO-3107 BLA on a standard review timeline rather than the accelerated review timeline that the Company touted the prospects of. The Company further stated that it did not plan to seek approval under the standard review timeline and planned to request a meeting with the FDA to discuss pursuing accelerated approval.

On this news, Inovio’s stock price fell $0.56, or 24.45%, to close at $1.73 per share on December 29, 2025, thereby injuring investors further.

Contact Us To Participate or Learn More:

If you purchased Inovio securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:

Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Telephone: (215) 638-4847
Email: howardsmith@howardsmithlaw.com
Visit our website at: www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

Industry:

Law Offices of Howard G. Smith

NASDAQ:INO
Release Versions
English

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

More News From Law Offices of Howard G. Smith

Securities Fraud Class Action Lawsuit Pending Against O-I Glass, Inc.: The Law Offices of Howard G. Smith Highlights Lead Plaintiff Deadline

BENSALEM, Pa.--(BUSINESS WIRE)--O-I Glass, Inc. ("O-I Glass" or the "Company") (NYSE: OI) is the subject of a securities fraud class action lawsuit filed on behalf of investors who purchased or otherwise acquired the Company's securities from March 14, 2025 through July 28, 2026, inclusive. The Law Offices of Howard G. Smith today reported the lawsuit, Bryan v. O-I Glass, Inc. et al., which was filed on October 29, 2026 in the U.S. District Court Ohio Northern District Court (Case No. 3:26-cv-02...

Did You Lose Money on DaVita Inc. Stock? The Law Offices of Howard G. Smith Announces Securities Fraud Investigation After 6.23% Share Price Decline

BENSALEM, Pa.--(BUSINESS WIRE)--Investors who suffered losses on DaVita Inc. ("DaVita" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today reported that it is conducting a securities fraud investigation on behalf of DaVita Inc. (NYSE: DVA) investors into whether the Company may have violated the federal securities laws. The investigation comes after a October 20, 2026 disclosure concerning DaVita Inc.Investors with losses on DaVita Inc. secur...

Deadline Alert: UP Fintech Holding Limited Stockholders Face December 28, 2026 Lead Plaintiff Deadline in Securities Fraud Class Action, The Law Offices of Howard G. Smith Highlights

BENSALEM, Pa.--(BUSINESS WIRE)--UP Fintech Holding Limited ("UP Fintech" or the "Company") (NASDAQ: TIGR) investors who wish to serve as lead plaintiff in a pending securities fraud class action lawsuit must move the Court by December 28, 2026. The suit was filed on behalf of investors who purchased or otherwise acquired the Company's securities from April 22, 2024 through June 2, 2026, inclusive. The Law Offices of Howard G. Smith today highlighted the deadline in the case, Liao v. Up Fintech H...
Back to Newsroom